Pedro Depablos-Velasco1, Emilio Salguero-Chaves2, Julio Mata-Poyo3, Beatriz Derivas-Otero4, Ricardo García-Sánchez5, Pablo Viguera-Ester6. 1. Departamento de Endocrinología y Metabolismo, Hospital Dr. Negrín, Universidad de Las Palmas, Las Palmas de Gran Canaria, España. 2. Servicio Extremeño de Salud, Centro de Atención primaria de Valdepasillas, Badajoz, España. 3. Servicio Extremeño de Salud, Centro de Atención primaria de Tabara, Zamora, España. 4. Departamento Médico, AstraZeneca Farmacéutica Spain, S.A., Madrid, España. 5. Departamento Médico, Bristol-Myers Squibb, Madrid, España. 6. Departamento Médico, AstraZeneca Farmacéutica Spain, S.A., Madrid, España. Electronic address: Pablo.viguera@astrazeneca.com.
Abstract
OBJECTIVES: Few studies are available on quality of life and treatment satisfaction of patients with type 2 diabetes mellitus (T2DM). Both of them were the primary objectives of the PANORAMA (NCT00916513) study. Metabolic control, treatment patterns, and management by healthcare professionals were also evaluated. MATERIAL AND METHODS: This multicenter, cross-sectional, observational study randomly recruited>40 year-old patients with T2DM from Spanish healthcare centers. HbA1c was measured using the same technique in all patients, who also completed quality of life (EQ-5D and ADDQoL) and treatment satisfaction (DTSQ) questionnaires and the Hypoglycemia Fear Survey (HFS-II). RESULTS: Fifty-four investigators recruited 751 patients, 60.3% of whom had HbA1c levels <7%. Approximately 25% of patients on monotherapy had HbA1c values ≥ 7%, Patients with longer disease duration and more complex treatments, especially with insulin, showed the poorer control. Despite good overall treatment satisfaction (mean 29.3±6.1, 0 to 36-point scale), patients with a poorer metabolic control, previous hypoglycemia episodes, and more complex therapies had a worse QoL and a greater fear of suffering hypoglycemia. CONCLUSIONS: Despite advances in metabolic control, there are still areas to improve. Early addition of safe drugs to monotherapy would help achieve control objectives without increasing the risk of hypoglycemia, and delaying the start of insulin therapy. This would also improve QoL and treatment satisfaction.
OBJECTIVES: Few studies are available on quality of life and treatment satisfaction of patients with type 2 diabetes mellitus (T2DM). Both of them were the primary objectives of the PANORAMA (NCT00916513) study. Metabolic control, treatment patterns, and management by healthcare professionals were also evaluated. MATERIAL AND METHODS: This multicenter, cross-sectional, observational study randomly recruited>40 year-old patients with T2DM from Spanish healthcare centers. HbA1c was measured using the same technique in all patients, who also completed quality of life (EQ-5D and ADDQoL) and treatment satisfaction (DTSQ) questionnaires and the Hypoglycemia Fear Survey (HFS-II). RESULTS: Fifty-four investigators recruited 751 patients, 60.3% of whom had HbA1c levels <7%. Approximately 25% of patients on monotherapy had HbA1c values ≥ 7%, Patients with longer disease duration and more complex treatments, especially with insulin, showed the poorer control. Despite good overall treatment satisfaction (mean 29.3±6.1, 0 to 36-point scale), patients with a poorer metabolic control, previous hypoglycemia episodes, and more complex therapies had a worse QoL and a greater fear of suffering hypoglycemia. CONCLUSIONS: Despite advances in metabolic control, there are still areas to improve. Early addition of safe drugs to monotherapy would help achieve control objectives without increasing the risk of hypoglycemia, and delaying the start of insulin therapy. This would also improve QoL and treatment satisfaction.
Keywords:
Calidad de vida; Diabetes mellitus tipo 2; Quality of life; Satisfacción con el tratamiento; Treatment satisfaction; Type 2 diabetes mellitus
Authors: Andres Pichon-Riviere; Vilma Irazola; Andrea Beratarrechea; Andrea Alcaraz; Carolina Carrara Journal: Int J Health Policy Manag Date: 2015-04-10
Authors: Nuria Alcubierre; Esther Rubinat; Alicia Traveset; Montserrat Martinez-Alonso; Marta Hernandez; Carmen Jurjo; Didac Mauricio Journal: Health Qual Life Outcomes Date: 2014-08-20 Impact factor: 3.186
Authors: Dácil Alvarado-Martel; M Angeles Ruiz Fernández; Maribel Cuadrado Vigaray; Armando Carrillo; Mauro Boronat; Ana Expósito Montesdeoca; Lía Nattero Chávez; Maite Pozuelo Sánchez; Pino López Quevedo; Ana D Santana Suárez; Natalia Hillman; David Subias; Pilar Martin Vaquero; Lourdes Sáez de Ibarra; Didac Mauricio; Pedro de Pablos-Velasco; Francisco J Nóvoa; Ana M Wägner Journal: Front Psychol Date: 2017-05-31
Authors: Nuria Alcubierre; Montserrat Martinez-Alonso; Joan Valls; Esther Rubinat; Alicia Traveset; Marta Hernández; Maria Dolores Martínez-González; Minerva Granado-Casas; Carmen Jurjo; Jesus Vioque; Eva Maria Navarrete-Muñoz; Didac Mauricio Journal: Health Qual Life Outcomes Date: 2016-05-04 Impact factor: 3.186
Authors: Sa'ed H Zyoud; Samah W Al-Jabi; Waleed M Sweileh; Diana A Arandi; Sujood A Dabeek; Hiba H Esawi; Remà H Atyeh; Hadeel A Abu-Ali; Yazan I Sleet; Baraa M Abd-Alfatah; Rahmat Awang Journal: J Clin Transl Endocrinol Date: 2015-03-31